Hematologic Cancers

Aphexda Approved for Stem Cell Mobilization for ASCT in Multiple Myeloma

By

Brian Park, PharmD

Publish Date September 19, 2023

Aphexda is expected to be available in September 2023.

Global Incidence of Early-Onset Cancers Rose 80% From 1990 to 2019

By

Jen Smith

Publish Date September 14, 2023

New data suggest that, from 1990 to 2019, the global incidence of early-onset cancer increased by nearly 80%, and the rate of early-onset cancer deaths increased by nearly 30%.

Risk of Infections Higher With Bispecific Antibody Therapy for Multiple Myeloma

By

Jennifer Larson

Publish Date September 8, 2023

Researchers sought to assess and better characterize the risk of infection in patients with MM treated with bispecific antibodies.

CAR‑HEMATOTOX Score Shows Prognostic Utility for CAR‑T Therapy in Relapsed/Refractory Multiple Myeloma

By

Lauren Dembeck, PhD

Publish Date September 1, 2023

Researchers sought to determine whether the CAR‑HEMATOTOX score would have prognostic value for both toxicity and treatment response in patients with R/R MM receiving CAR-T therapy.

Team-Based Strategies Could Reduce Racial Disparities in Multiple Myeloma Care

By

Megan Garlapow, PhD

Publish Date August 30, 2023

A large-scale study sought to compare the perspectives of healthcare team members with those of Black/Hispanic patients and White patients to determine potential ways to mitigate disparities.